Literature DB >> 10507958

Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion.

S K Brodine1, R A Shaffer, M J Starkey, S A Tasker, J L Gilcrest, M K Louder, A Barile, T C VanCott, M T Vahey, F E McCutchan, D L Birx, D D Richman, J R Mascola.   

Abstract

BACKGROUND: Regular testing of military personnel identifies early HIV infection; this identification provides a sentinel cohort in which to describe the evolving molecular epidemiology of HIV-1 transmission.
OBJECTIVE: To describe the prevalence and epidemiologic correlates associated with the acquisition of non-subtype B and drug-resistant HIV infections.
DESIGN: Cross-sectional study.
SETTING: Military referral hospital. PATIENTS: 95 military personnel with HIV-1 seroconversion. MEASUREMENTS: Self-reported questionnaire, CD4 cell counts, plasma HIV-1 RNA levels, and nucleic acid sequence analysis for drug-resistant mutations and HIV-1 genetic subtype.
RESULTS: 95 patients were enrolled between February 1997 and February 1998. The likely geographic location of HIV-1 acquisition was overseas in 8% of patients, the United States in 68%, and either overseas or the United States in 24%. Seven patients (7.4%) had subtype E infection; the remainder had subtype B infection. Eight of 31 (26%) treatment-naive patients had mutations in the reverse transcriptase or protease gene associated with drug resistance.
CONCLUSIONS: The percentage of HIV-1 non-subtype B infection and antiretroviral drug-resistant mutations was relatively high in U.S. military personnel with recently acquired HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507958     DOI: 10.7326/0003-4819-131-7-199910050-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

1.  Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.

Authors:  Ana T Dumans; Marcelo A Soares; Danuta Pieniazek; Marcia L Kalish; Veronique De Vroey; Kurt Hertogs; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  The US Military HIV Natural History Study: Informing Military HIV Care and Policy for Over 30 Years.

Authors:  Brian K Agan; Anuradha Ganesan; Morgan Byrne; Robert Deiss; Christina Schofield; Ryan C Maves; Jason Okulicz; Xiuping Chu; Thomas O'Bryan; Tahaniyat Lalani; Karl Kronmann; Tomas Ferguson; Merlin L Robb; Timothy J Whitman; Timothy H Burgess; Nelson Michael; Edmund Tramont
Journal:  Mil Med       Date:  2019-11-01       Impact factor: 1.437

3.  Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

Authors:  S Emery; S Bodrug; B A Richardson; C Giachetti; M A Bott; D Panteleeff; L L Jagodzinski; N L Michael; R Nduati; J Bwayo; J K Kreiss; J Overbaugh
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B.

Authors:  Linda L Jagodzinski; John D Cooley; Mark Weber; Nelson L Michael
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.

Authors:  J G Garcia-Lerma; S Nidtha; K Blumoff; H Weinstock; W Heneine
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

Authors:  M Janini; M Rogers; D R Birx; F E McCutchan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort.

Authors:  Alan R Lifson; Elizabeth M Krantz; Lynn E Eberly; Matthew J Dolan; Vincent C Marconi; Amy C Weintrob; Nancy F Crum-Cianflone; Anuradha Ganesan; Patricia L Grambsch; Brian K Agan
Journal:  AIDS Res Ther       Date:  2011-01-18       Impact factor: 2.250

8.  Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.

Authors:  Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Vincent C Marconi; Anuradha Ganesan; Amy Weintrob; Robert V Barthel; Brian K Agan
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

9.  Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.

Authors:  J Gerardo García-Lerma; Hamish MacInnes; Diane Bennett; Hillard Weinstock; Walid Heneine
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV.

Authors:  Lilian A Inocencio; Anderson A Pereira; Maria Cecilia A Sucupira; José Carlos C Fernandez; Célia P Jorge; Denise Fc Souza; Helena T Fink; Ricardo S Diaz; Irina M Becker; Theodoro A Suffert; Monica B Arruda; Olinda Macedo; Mariangela Bg Simão; Amilcar Tanuri
Journal:  J Int AIDS Soc       Date:  2009-09-18       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.